Quality assessment | Number of patients | Effect | Quality | Importance | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Number of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | LAIV | IIV | RR (95% CI) | Absolute | ||
Laboratory confirmed influenza (follow-up; assessed with: PCR or viral culture) | ||||||||||||
Randomized trials | ⊕ ⊕ ⊕ ⊕ HIGH | CRITICAL | ||||||||||
Influenza like illness (follow-up; assessed with) | ||||||||||||
Randomized trials | ⊕ ⊕ ⊕ ⊕ HIGH | IMPORTANT | ||||||||||
Hospitalization (follow-up; assessed with) | ||||||||||||
Randomized trials | ⊕ ⊕ ⊕ ⊕ HIGH | CRITICAL | ||||||||||
Medically attended respiratory illness (follow-up; assessed with) | ||||||||||||
Randomized trials | ⊕ ⊕ ⊕ ⊕ HIGH | CRITICAL | ||||||||||
Fever due to vaccination (follow-up mean, assessed with) | ||||||||||||
Randomized trials | ⊕ ⊕ ⊕ ⊕ HIGH | IMPORTANT | ||||||||||
Guillain-Barre syndrome (follow-up mean, assessed with) | ||||||||||||
Observational study | ⊕ ⊕ ΟΟ LOW | IMPORTANT | ||||||||||
Anaphylaxis (follow-up mean, assessed with) | ||||||||||||
Observational study | ⊕ ⊕ ΟΟ LOW | CRITICAL |